A C Hesseling
Overview
Explore the profile of A C Hesseling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Viljoen L, Hendricks P, Hoddinott G, Vanqa N, Osman M, Hesseling A, et al.
Public Health Action
. 2022 Sep;
12(3):121-127.
PMID: 36160718
Background: In South Africa, failure to link individuals diagnosed with TB to care remains an important gap in the TB care cascade. Compared to people diagnosed at primary healthcare (PHC)...
22.
Nel Van Zyl K, Whitelaw A, Hesseling A, Seddon J, Demers A, Newton-Foot M
BMC Microbiol
. 2022 Aug;
22(1):201.
PMID: 35978282
Background: The fungal microbiome, or mycobiome, is a poorly described component of the gut ecosystem and little is known about its structure and development in children. In South Africa, there...
23.
Hirsch-Moverman Y, Howard A, Yuengling K, Lebelo L, Frederix K, Hesseling A, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(7):612-622.
PMID: 35768915
Child contact management (CCM) is a recognized strategy to prevent TB; however, implementation is suboptimal. PREVENT was a cluster-randomized trial that evaluated the effectiveness and acceptability of a community-based intervention...
24.
Alffenaar J, Stocker S, Davies Forsman L, Garcia-Prats A, Heysell S, Aarnoutse R, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(6):483-499.
PMID: 35650702
Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance...
25.
Lopez-Varela E, Garcia-Prats A, Seddon J, Draper H, Winckler J, van der Laan L, et al.
Int J Tuberc Lung Dis
. 2022 Jan;
26(2):133-141.
PMID: 35086625
The treatment of rifampicin-resistant TB (RR-TB) in children is evolving rapidly. As newer regimens are introduced into routine care, it is vital to compare their outcome and safety with well-characterised...
26.
Marx F, Meehan S, Jivan D, Dunbar R, Hoddinott G, Hesseling A, et al.
Int J Tuberc Lung Dis
. 2021 Dec;
26(1):26-32.
PMID: 34969425
To investigate the uptake and usage of a WhatsApp-based interactive communication strategy to avert pre-diagnosis loss to follow-up (LTFU) from TB care in a high-incidence setting. We enrolled adults (≥18...
27.
Winckler J, Schaaf H, Draper H, McIlleron H, Norman J, van der Laan L, et al.
Int J Tuberc Lung Dis
. 2021 Oct;
25(11):896-902.
PMID: 34686231
High-dose isoniazid (INH) (15-20 mg/kg/day) could be administered to overcome low-level INH resistance, but pharmacokinetic data are sparse. This observational study included South African children (<15 years) receiving INH as...
28.
Purchase S, Batist E, Mmile N, Nkosi S, Workman J, Martinson N, et al.
Int J Tuberc Lung Dis
. 2021 Oct;
25(10):814-822.
PMID: 34615578
Recruitment to randomised clinical trials can be challenging and slow recruitment has serious consequences. This study aimed to summarise and reflect on the challenges in enrolling young children to a...
29.
Winckler J, Draper H, Schaaf H, van der Laan L, Hesseling A, Garcia-Prats A
Int J Tuberc Lung Dis
. 2020 Dec;
24(12):1316-1318.
PMID: 33317680
No abstract available.
30.
van der Zalm M, Walters E, Claassen M, Palmer M, Seddon J, Demers A, et al.
BMC Infect Dis
. 2020 Dec;
20(1):924.
PMID: 33276721
Background: The presentation of pulmonary tuberculosis (PTB) in young children is often clinically indistinguishable from other common respiratory illnesses, which are frequently infections of viral aetiology. As little is known...